| dbo:abstract |
Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well. (en) ラドスチギル(Ladostigil)は、アルツハイマー病やレビー小体型認知症、パーキンソン病のような神経変性疾患の治療のために開発された薬である。アセチルコリンエステラーゼ及びの可逆の阻害剤、及びの不可逆の阻害剤として作用し、またリバスチグミンやラサギリンの作用機序と組み合わさって単一の分子として作用する。神経防護作用に加え、ラドスチギルはGDNFやBDNF等の神経栄養因子の発現を促し、神経発生の誘導によって、神経変性疾患による損傷を回復する可能性が考えられている。ラドスチギルはまた抗うつ効果も持ち、そのような病気でよく見られるうつと不安の併発の治療にも効果が期待されている。 (ja) |
| dbo:casNumber |
209394-27-4 |
| dbo:fdaUniiCode |
SW3H1USR4Q |
| dbo:kegg |
D03239 |
| dbo:pubchem |
208907 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Ladostigil.svg?width=300 |
| dbo:wikiPageID |
25278076 (xsd:integer) |
| dbo:wikiPageLength |
4771 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1123035940 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Enzyme_inhibitor dbr:Rivastigmine dbc:Carbamates dbr:Brain-derived_neurotrophic_factor dbc:Acetylcholinesterase_inhibitors dbr:Antidepressant dbr:Anxiety dbr:Lewy_body_disease dbr:Major_depressive_disorder dbr:Drug dbr:Acetylcholinesterase dbc:Monoamine_oxidase_inhibitors dbc:Propargyl_compounds dbr:Alzheimer's_disease dbr:Parkinson's_disease dbr:Glial_cell_line-derived_neurotrophic_factor dbc:1-Aminoindanes dbr:Cholinesterase_inhibitor dbr:Butyrylcholinesterase dbr:Neurotrophic_factor dbr:Rasagiline dbr:Selegiline dbr:Mechanism_of_action dbr:Neurogenesis dbr:Mofegiline dbr:Monoamine_oxidase_B dbr:Neuroprotective dbr:Reversible_inhibition dbr:Irreversible_inhibition dbr:Neurodegenerative_disorder |
| dbp:atcPrefix |
None (en) |
| dbp:c |
16 (xsd:integer) |
| dbp:casNumber |
209394 (xsd:integer) |
| dbp:chemspiderid |
181005 (xsd:integer) |
| dbp:h |
20 (xsd:integer) |
| dbp:iupacName |
[-3-indan-5-yl]-N-propylcarbamate (en) |
| dbp:kegg |
D03239 (en) |
| dbp:legalStatus |
Uncontrolled (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
208907 (xsd:integer) |
| dbp:routesOfAdministration |
Oral (en) |
| dbp:synonyms |
[N-propargyl--aminoindan-5yl]-N-propylcarbamate (en) |
| dbp:unii |
SW3H1USR4Q (en) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Antioxidants dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Acetylcholine_metabolism_and_transport_modulators dbt:Monoamine_metabolism_modulators |
| dct:subject |
dbc:Carbamates dbc:Acetylcholinesterase_inhibitors dbc:Monoamine_oxidase_inhibitors dbc:Propargyl_compounds dbc:1-Aminoindanes |
| gold:hypernym |
dbr:Agent |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCarbamates yago:WikicatMolecularFormulas yago:Abstraction100002137 yago:Acetylene114600742 yago:AliphaticCompound114601294 yago:Carbamate114792281 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Formula106816935 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 dbo:Drug yago:Salt115010703 yago:Statement106722453 yago:Substance100019613 yago:WikicatAlkynes umbel-rc:DrugProduct |
| rdfs:comment |
ラドスチギル(Ladostigil)は、アルツハイマー病やレビー小体型認知症、パーキンソン病のような神経変性疾患の治療のために開発された薬である。アセチルコリンエステラーゼ及びの可逆の阻害剤、及びの不可逆の阻害剤として作用し、またリバスチグミンやラサギリンの作用機序と組み合わさって単一の分子として作用する。神経防護作用に加え、ラドスチギルはGDNFやBDNF等の神経栄養因子の発現を促し、神経発生の誘導によって、神経変性疾患による損傷を回復する可能性が考えられている。ラドスチギルはまた抗うつ効果も持ち、そのような病気でよく見られるうつと不安の併発の治療にも効果が期待されている。 (ja) Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule. In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis. Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen (en) |
| rdfs:label |
Ladostigil (en) ラドスチギル (ja) |
| owl:sameAs |
freebase:Ladostigil yago-res:Ladostigil wikidata:Ladostigil dbpedia-ja:Ladostigil dbpedia-sh:Ladostigil dbpedia-sr:Ladostigil https://global.dbpedia.org/id/3TKV4 |
| prov:wasDerivedFrom |
wikipedia-en:Ladostigil?oldid=1123035940&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ladostigil.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Ladostigil |
| is dbo:wikiPageRedirects of |
dbr:C16H20N2O2 |
| is dbo:wikiPageWikiLink of |
dbr:List_of_adrenergic_drugs dbr:List_of_dopaminergic_drugs dbr:2-Aminoindane dbr:C16H20N2O2 dbr:Acetylcholinesterase_inhibitor dbr:Rasagiline dbr:Mofegiline dbr:List_of_drugs:_La |
| is foaf:primaryTopic of |
wikipedia-en:Ladostigil |
